Home - Blacksmith Medicines
Purpose-Built Platform forMetalloenzyme-Targeted Medicines. Blacksmith Medicines. 3033 Science Park Road Suite 270 San Diego, CA 92121 | Media: amy@juniper-point.com.
About Us - Blacksmith Medicines
At Blacksmith Medicines, we seek to honor that age-old tradition of hard-work and invention through the discovery and development of small molecule inhibitors of metal-dependent enzymes using our modern toolset.
Blacksmith Medicines launches with seed funding and a research ...
SAN DIEGO, California, January 8, 2021 – Blacksmith Medicines, Inc. (Blacksmith), a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, announced today that it has secured seed funding and has entered into a research collaboration with Eli Lilly and Company ...
BLACKSMITH MEDICINES ANNOUNCES MERGER WITH FORGE …
SAN DIEGO, Jan. 2, 2023 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), and Forge Therapeutics (Forge), announce today that the companies have signed a definitive merger agreement to...
Blacksmith Medicines - LinkedIn
Blacksmith Medicines and Zoetis, the world’s leading animal health company, announced today a collaboration to discover and develop novel antibiotics for animal health. Read more about...
Blacksmith Medicines and Zoetis Announce Research …
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, and Zoetis,...
Eli Lilly Partners with Blacksmith Medicines in $300 Million Seed ...
2021年1月8日 — Blacksmith Medicines announced on Friday it had secured a multimillion dollar seed funding deal from Eli Lilly and has entered into a research collaboration with the Indianapolis-based pharmaceutical giant to advance human metalloenzyme targets.
Blacksmith Medicines announces merger with Forge …
2023年1月2日 — SAN DIEGO, California, January 2, 2023 – Blacksmith Medicines, Inc. (Blacksmith), and Forge Therapeutics (Forge), announce today that the companies have signed a definitive merger agreement to leverage their combined chemistry platforms, creating a leading biopharma dedicated to discovering and developing medicines targeting a large class of ...
Blacksmith returns to Forge as companies remerge - Fierce Biotech
2023年1月3日 — It’s back to the workshop for Blacksmith Medicines as it melds with originating company Forge Therapeutics to produce a metalloenzymes-focused biotech that will initially hammer out therapies ...
Blacksmith Medicines Announces $3.3M in Funding from NIAID ... - BioSpace
2024年2月21日 — Blacksmith, using its proprietary chemistry platform, has developed novel non-hydroxamate inhibitors of LpxC that are safe and effective in animal models of Gram-negative infection and are able to kill Gram-negative ‘superbugs’ where other antibiotics are ineffective.